Enterprise Value
28.05M
Cash
22.51M
Avg Qtr Burn
-3.887M
Short % of Float
2.86%
Insider Ownership
2.92%
Institutional Own.
12.17%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MAT2203 (Oral Amphotericin B) Details Meningitis, Cryptococcal meningitis, Azole-resistant infections, C. krusei infection, Fungal infections | Phase 3 Initiation | |
LYPDISO (MAT9001) (Omega-3 Drug) Details Cardiovascular disease | Failed Discontinued |